Capital Group Municipal Income ETF (CGMU)
- Previous Close
27.32 - Open
27.34 - Bid --
- Ask --
- Day's Range
27.32 - 27.34 - 52 Week Range
25.32 - 27.54 - Volume
174,430 - Avg. Volume
821,878 - Net Assets 2.4B
- NAV 27.27
- PE Ratio (TTM) --
- Yield 3.12%
- YTD Daily Total Return 3.27%
- Beta (5Y Monthly) 0.00
- Expense Ratio (net) 0.27%
The fund will normally invest at least 80% of its assets in, or derive at least 80% of its income from, securities that are exempt from regular federal income tax. The fund will invest up to 30% of its assets in securities that may subject the investors to federal alternative minimum tax. The fund invests at least 65% in debt securities rated BBB- or better or Baa3 or better by NRSRO designated by the fund’s investment adviser. The fund is non-diversified.
Capital Group
Fund Family
Muni National Interm
Fund Category
2.4B
Net Assets
2022-10-25
Inception Date
Performance Overview: CGMU
View MoreTrailing returns as of 10/11/2024. Category is Muni National Interm.
People Also Watch
Related ETF News
View MoreResearch Reports: CGMU
View MorePfizer's Diverse Portfolio of Drugs and Vaccines Supports a Wide Moat
Pfizer is one of the world's largest pharmaceutical firms, with annual sales close to $50 billion (excluding covid-19-related product sales). While it historically sold many types of healthcare products and chemicals, now prescription drugs and vaccines account for the majority of sales. Top sellers include pneumococcal vaccine Prevnar 13, cancer drug Ibrance, and cardiovascular treatment Eliquis. Pfizer sells these products globally, with international sales representing close to 50% of total sales. Within international sales, emerging markets are a major contributor.
RatingPrice TargetWhat does Argus have to say about BB?
BLACKBERRY LTD has an Investment Rating of SELL; a target price of $2.000000; an Industry Subrating of High; a Management Subrating of Low; a Safety Subrating of Low; a Financial Strength Subrating of Medium; a Growth Subrating of Low; and a Value Subrating of Low.
RatingPrice TargetJohnson & Johnson Earnings: Largely in Line as New Products Ready to Offset Stelara Biosimilars
Johnson & Johnson is the world's largest and most diverse healthcare firm. It has two divisions: pharmaceutical and medical devices. These now represent all of the company's sales following the divestment of the consumer business, Kenvue, in 2023. The drug division focuses on the following therapeutic areas: immunology, oncology, neurology, pulmonary, cardiology, and metabolic diseases. Geographically, just over half of total revenue is generated in the United States.
RatingPrice TargetNew products and M&A drive 2024 growth
Johnson & Johnson is a diversified global healthcare company that develops, manufactures and markets products in two business segments: Innovative Medicine (formerly Pharmaceuticals) and MedTech.
RatingPrice Target